This is default featured slide 1 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 2 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 3 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 4 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 5 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

Drugmakers must report safety data from launch date, not approval date: CDSCO

India's drug regulator has issued a new directive for pharmaceutical companies. Periodic Safety Update Reports for new drugs must now be submitted from the actual market launch date. This change aims to strengthen patient safety monitoring. Previously, reports were based on the regulatory approval date. The new rule ensures that real-world data from patients is included.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/grlCBG9
via IFTTT

India's hospital sector enters new growth cycle as AI and capacity expansion reshape care: Report

India's hospital sector is set for significant growth over the next decade. Demand is rising due to increased income, insurance, an aging population, and chronic diseases. Hospitals are expanding capacity to meet a critical bed shortage. Private insurance is growing, boosting revenue. This expansion offers substantial opportunities for investors and operators in the healthcare industry.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mWBKsXV
via IFTTT

EQT emerges sole bidder for OmniActive Health Technologies

Swedish investment powerhouse EQT is now leading the charge as the exclusive bidder for OmniActive Health Technologies, following the rejection of a competing offer from Temasek and Novo Holdings. Known for its robust presence in the nutraceutical industry, OmniActive is under the umbrella of TA Associates and has a strong export footprint in the United States.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/91pvszd
via IFTTT

MSD India ropes in Madhuri Dixit for cervical cancer awareness drive

US pharma major MSD has partnered with Bollywood actor Madhuri Dixit for a nationwide cervical cancer awareness program in India. The initiative aims to encourage conversations about women's preventive healthcare and prompt discussions with doctors regarding cervical cancer and its prevention. Digital films featuring Dixit have been released to amplify the campaign's reach.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EPz24lq
via IFTTT

Hantavirus outbreak on cruise ship: India monitors situation, no cases on Indian soil

The Union Health Ministry is monitoring hantavirus cases on the cruise ship MV Hondius, where three deaths and five confirmed infections have occurred. India has no domestic cases and its surveillance networks are active. The Andes strain, with limited human-to-human transmission, has been identified, and the WHO assesses the public health risk as low.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yKRBPXu
via IFTTT

India faces no immediate public health threat from hantavirus: NIV chief

Two Indian nationals aboard a cruise ship have reportedly contracted hantavirus. Indian health officials assure the public that these cases appear isolated. There is no immediate public health threat to India. Experts confirm hantavirus does not spread easily among people. India possesses adequate laboratory capacity for diagnosis. Standard rodent control and sanitation remain key preventive measures.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gkVsenY
via IFTTT

Semaglutide race: Torrent grabs 38% market share

Over a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of Novo Nordisk's patent for the innovator molecule in end-March. They generated about ₹44 crore in generic semaglutide sales in April.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MRljJ4P
via IFTTT